TABLE 3.
Effects of baseline characteristics on treatment result (success vs failure; n = 136).
| 6‐month | p | 18‐month | p | |||
|---|---|---|---|---|---|---|
| Success (n = 103) | Failure (n = 33) | Success (n = 46) | Failure (n = 25) | |||
| Age | ||||||
| 50–65 | 44 (43%) | 10 (30%) | 0.41 | 21 (46%) | 12 (48%) | 0.96 |
| 66–75 | 41 (40%) | 17 (52%) | 20 (43%) | 10 (40%) | ||
| >75 | 18 (17%) | 6 (18%) | 54 (11%) | 3 (12%) | ||
| MCCL, mm, median (IQR) | 7 (5, 9) | 8 (5, 10) | 0.07 | 7 (5,10) | 7 (4,8) | 0.36 |
| PSA, ng/mL | ||||||
| Median (IQR) | 6.8 (4.9, 9.2) | 7.2 (4.9, 13.0) | 0.40 | 6.8 (4.1, 9.6) | 6.6 (5.2, 8.9) | 0.61 |
| <4 | 11 (11%) | 2 (6%) | 0.08 | 10 (22%) | 1 (4%) | 0.07 |
| 4–10 | 71 (69%) | 18 (55%) | 25 (54%) | 20 (80%) | ||
| >10 | 21(20%) | 13 (39%) | 11 (24$) | 4 (16%) | ||
| Prostate volume, cc, | ||||||
| Median (IQR) | 35.8 (27.7, 47.9) | 33 (24, 43) | 0.11 | 49.5 (34, 58.8) | 36 (31.8, 48) | 0.03 |
| ≤40 | 44 (43%) | 21 (64%) | 0.11 | 18 (39%) | 15 (60%) | 0.04 |
| 41–55 | 32 (31%) | 7 (21%) | 12 (26%) | 8 (32%) | ||
| ≤40 | 27 (26%) | 5 (15%) | 16 (35%) | 2 (8%) | ||
| PSA density, ng/mL/cc | ||||||
| Median (IQR) | 0.15 (0.12, 0.22) | 0.16 (0.11, 0.39) | 0.29 | 0.15 (0.08, 0.20) | 0.19 (0.14, 0.27) | 0.03 |
| ≤0.15 | 51 (50%) | 15 (45%) | 0.65 | 23 (50%) | 10 (40%) | 0.42 |
| >0.15 | 51 (50%) | 18 (55%) | 23 (50%) | 15 (60%) | ||
| % Free PSA, median (IQR) a | 17 (13, 23) | 13 (10, 17) | 0.001 | 13.5 (10, 18) | 14 (11, 17) | 0.86 |
| PIRADS grade | ||||||
| 1–3 | 21 (21%) | 2 (6%) | 0.03 b | 14 (31%) | 5 (21%) | 0.27 b |
| 4 | 48 (48%) | 13 (39%) | 19 (42%) | 13 (54%) | ||
| 5 | 32 (32%) | 18 (55%) | 12 (27%) | 6 (25%) | ||
| ROI location | ||||||
| Anterior | 66 (64%) | 22 (67%) | 0.79 | 19 (41%) | 4 (16%) | 0.03 |
| Posterior | 37 (36%) | 11 (33%) | 27 (59%) | 21 (84%) | ||
| Laterality | ||||||
| Left | 61 (59%) | 19 (58%) | 0.87 | 27 (59%) | 14 (56%) | 0.83 |
| Right | 42 (41%) | 14 (42%) | 19 (41%) | 11 (44%) | ||
Note: R0I diameter, which was the only significant baseline predictor of biopsy result in multivariate analysis, is treated in eTable 1.
a
6‐month Success n = 93 vs Failure n = 31, 18‐month Success n = 38 vs Failure n = 22.
b
Wilcoxon rank sum test.